---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-069892"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:31:40.307098+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CRISPR amends Vertex collaboration on exa-cel; $20M contingent payment, cost deferral adjustments

## Summary
- CRISPR agrees to pay Vertex $20M contingent payment upon specified event under Amendment No. 1 for exa-cel.
- Deferral of CRISPR's share of costs capped at $25M annually; amounts offset against future exa-cel profitability.
- Amendment allocates costs from a new third-party license agreement entered by Vertex; some details redacted.
- Changes timing and portion of CRISPR's permitted cost deferrals under certain specified circumstances.

## SEC filing metadata
- accession: 0000950170-23-069892
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017023069892/0000950170-23-069892-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017023069892/crsp-20231212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-069892
- JSON: https://secwatch.observer/filing/0000950170-23-069892.json
- Plain text: https://secwatch.observer/filing/0000950170-23-069892.txt

## Key facts
- Material Agreements
  CRISPR Therapeutics AG amended Amendment No. 1 with Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (effective 2023-12-12).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited
  - Effective: 2023-12-12
  source text: On December 12, 2023, CRISPR Therapeutics AG, CRISPR Therapeutics Limited, CRISPR Therapeutics, Inc., and TRACR Hematology Ltd (together, “CRISPR”) entered into an amendment to the Amended and Restated Joint Development and Commercialization Agreement (the “Amendment No. 1”) with Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, “Vertex”), related to the global development, manufacturing, and commercialization of exagamglogene autotemcel, or exa-cel (formerly CTX001).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000095017023069892/0000950170-23-069892-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.